Advanced in Congenital Hepatic Fibrosis

Dr. Norah Terrault

Hepatology
USC Care Medical Group Inc
1520 San Pablo St, Fl 4, 
Los Angeles, CA 
Offers Telehealth
38 Years of Experience
Advanced in Congenital Hepatic Fibrosis
USC Care Medical Group Inc
1520 San Pablo St, Fl 4, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Norah Terrault is a Hepatologist in Los Angeles, California. Dr. Terrault has been practicing medicine for over 38 years and is rated as an Advanced provider by MediFind in the treatment of Congenital Hepatic Fibrosis. Her top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Her clinical research consists of co-authoring 386 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Keck Hospital Of USC
USC Verdugo Hills Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

USC CARE MEDICAL GROUP INC
1520 San Pablo St, Fl 4, Los Angeles, CA 90033
Other Locations
USC CARE MEDICAL GROUP INC
1500 San Pablo St, Los Angeles, CA 90033

Additional Areas of Focus

Dr. Terrault has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: Vitamin E
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Enrollment Status: Completed
Publish Date: February 23, 2022
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Enrollment Status: Completed
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

386 Total Publications

Erratum: HDV RNA assays: Performance characteristics, clinical utility, and challenges.
Erratum: HDV RNA assays: Performance characteristics, clinical utility, and challenges.
Journal: Hepatology (Baltimore, Md.)
Published: March 24, 2025
Similar Doctors
Advanced in Congenital Hepatic Fibrosis
Dr. Ke-qin Hu
Hepatology
Advanced in Congenital Hepatic Fibrosis
Dr. Ke-qin Hu
Hepatology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 mi)
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ke-qin Hu is a Hepatologist in Orange, California. Dr. Hu has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Congenital Hepatic Fibrosis. Their top areas of expertise are Hepatitis, Hepatitis B, Cirrhosis, and Hepatitis C.

Advanced in Congenital Hepatic Fibrosis
Dr. Omid Shaye
Hepatology
Advanced in Congenital Hepatic Fibrosis
Dr. Omid Shaye
Hepatology

Gastroenterology Associates Of Beverly Hills

8631 W 3rd St, 
Los Angeles, CA 
 (10.2 mi)
310-858-2224
Languages Spoken:
English
Offers Telehealth

Omid Shaye is a Hepatologist in Los Angeles, California. Dr. Shaye and is rated as an Advanced provider by MediFind in the treatment of Congenital Hepatic Fibrosis. His top areas of expertise are Trichohepatoenteric Syndrome, Cirrhosis, Intestinal Cancer, Endoscopy, and Colonoscopy.

Advanced in Congenital Hepatic Fibrosis
Dr. Tse-ling Fong
Hepatology
Advanced in Congenital Hepatic Fibrosis
Dr. Tse-ling Fong
Hepatology

Hoag Clinic

1 Hoag Dr, 
Newport Beach, CA 
 (34.1 mi)
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tse-ling Fong is a Hepatologist in Newport Beach, California. Dr. Fong has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Congenital Hepatic Fibrosis. Their top areas of expertise are Hepatitis, Hepatitis B, Jaundice, Visceromegaly, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Terrault's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 9 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile